CINJ received a P20 Cancer Center Support Grant (CCSG) planning grant in 1992. These dollars helped recruit a director and established the earliest infrastructure for an NCI-designated cancer center. In 1997, CINJ was awarded a P30 CCSG 1 that included $100,000 annually for developmental funds. It became apparent to the Director that this award could be used as a means to attract matching philanthropic dollars, and each year this amount of money has grown substantially. In 2000, CINJ successfully competed for a five-year CCSG renewal with an """"""""Excellent"""""""" priority score of 171. Developmental Funds received a rating of """"""""Outstanding"""""""" and $280,000 per year was awarded as requested. Based on advice and detailed review by the Internal and External Advisory Boards, plans were developed to enhance clinical and population sciences and interdisciplinary interactions. Developmental Funds played an important role in implementation of this plan by allowing the development of critical shared resources and the recruitment of outstanding new faculty that culminated in designation of CINJ as a Comprehensive Cancer Center in June, 2002. Developmental Funds are used to foster outstanding cancer research. During the last grant period, Developmental Funds provided essential support for outstanding new investigators, supported interdisciplinary pilot studies that led to translationally-focused collaborations, and helped establish new shared resources (e.g., Transcriptional Profiling, Transgenic and Knockout Mouse). In particular, Developmental Funds helped to strengthen the Division of Prevention, Control and Population Science and improved interactions between this division and the Divisions of Basic and Clinical Sciences. During the next grant period, CINJ shall use Developmental Funds to continue to enhance each of the three main scientific divisions of the center, Clinical Science (Prostate; Breast Cancer Research; Cancer Pharmacology/Developmental Therapeutics), Basic Science (Transcriptional Regulation and Oncogenesis; Cytokines, Cytokine Signaling and Cancer; and Molecular Mechanisms of Tumor Growth), and Prevention, Control and Population Science (Carcinogenesis and Chemoprevention; Population Science). To accomplish this aim, Developmental Funds will be used to help recruit new investigators, develop new shared resources, and fund additional pilot projects aimed at fostering inter-disciplinary collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA072720-12
Application #
7731616
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
12
Fiscal Year
2008
Total Cost
$362,344
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Type
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Modi, Parth K; Wang, Ye; Kirk, Peter S et al. (2018) The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology 117:50-56
Dai, Zhuqing; Feng, Simin; Liu, Anna et al. (2018) Anti-inflammatory effects of newly synthesized ?-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice. Food Res Int 109:350-357
Farber, Nicholas J; Faiena, Izak; Dombrovskiy, Viktor et al. (2018) Disparities in the Use of Continent Urinary Diversions after Radical Cystectomy for Bladder Cancer. Bladder Cancer 4:113-120
Lee, Jongin; Lee, Daehwan; Sim, Mikang et al. (2018) mySyntenyPortal: an application package to construct websites for synteny block analysis. BMC Bioinformatics 19:216
DeRenzo, Evan G; Moss, Joel; Singer, Eric A (2018) Implications of the Revised Common Rule for Human Participant Research. Chest :
Feng, Simin; Dai, Zhuqing; Liu, Anna B et al. (2018) Intake of stigmasterol and ?-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style diet. Biochim Biophys Acta Mol Cell Biol Lipids 1863:1274-1284
Song, Mihae; Kumaran, Muthu N; Gounder, Murugesan et al. (2018) Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecol Oncol 150:478-486
Khiabanian, Hossein; Hirshfield, Kim M; Goldfinger, Mendel et al. (2018) Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. JCO Precis Oncol 2018:
Rabadan, Raul; Bhanot, Gyan; Marsilio, Sonia et al. (2018) On statistical modeling of sequencing noise in high depth data to assess tumor evolution. J Stat Phys 172:143-155
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated whole breast irradiation is cost-effective-but is that enough to change practice? Transl Cancer Res 7:S469-S472

Showing the most recent 10 out of 775 publications